| Trial ID: | L0282 |
| Source ID: | NCT03576755
|
| Associated Drug: |
Spironolactone
|
| Title: |
Spironolactone Therapy In Young Women With NASH
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Spironolactone 100mg|Drug: Placebo oral capsule
|
| Outcome Measures: |
Change in liver stiffness on Magnetic Resonance Elastography (MRE)|Change in hepatic steatosis by Magnetic Resonance Proton Density Fat Fraction (PDFF)|Change in visceral adipose tissue (VAT) volume by Magnetic Resonance Imaging (MRI)|Change HOMA-IR (Homeostatic model assessment (HOMA) for insulin resistance (IR)).|Change in the NAFLD activity score (NAS 0-8).
|
| Sponsor/Collaborators: |
University of California, San Francisco
|
| Gender: |
Female
|
| Age: |
18 Years to 45 Years ?? (Adult)
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
30
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other
|
| Start Date: |
January 9, 2019
|
| Completion Date: |
July 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
August 25, 2021
|
| Locations: |
University of California San Francisco, San Francisco, California, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT03576755
|
